Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WAY170523
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Subcutaneous, Intraperitoneal, Implant
01
Overview
WAY170523 is a potent and selective small-molecule inhibitor of matrix metalloproteinase-13 (MMP-13, also known as collagenase-3), with an IC50 of 17 nM. It was originally developed by Wyeth Research (later acquired by Pfizer) using structure-based design and NMR spectroscopy. WAY170523 exhibits high selectivity for MMP-13, showing over 5800-fold selectivity against MMP-1, 56-fold against MMP-9, and over 500-fold against TNF-alpha converting enzyme (TACE). Due to its ability to prevent extracellular matrix degradation, it has been widely investigated in preclinical research for osteoarthritis, rheumatoid arthritis, cancer metastasis, and cardiac dysfunction.
- Other names
- N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide
02
Targets
ADAM17 (A disintegrin and metalloprotease 17)MMP13 (Matrix metalloproteinase-13)MMP1 (Matrix metalloproteinase-1)MMP9 (Matrix metalloproteinase-9)
Beyond the preview
Go deeper on WAY170523.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WAY170523.